BEMTUVIQ
Live / Applied — First extension granted (statement of use) (as of 29 Oct 2025)
What this means for you
Not registered yet, but its 04 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98583961
- Mark type
- Stylized text
- Filed
- 04 Jun 2024
- Published for opposition
- 01 Apr 2025
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of gastric and gastro-esophageal diseases, conditions or maladies
Owner
- Amgen Inc., Thousand Oaks, CA, US
- Amgen Inc., Thousand Oaks, CA, US
Prosecution history
- 29 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Oct 2025 — SOU EXTENSION 1 GRANTED
- 28 Oct 2025 — SOU EXTENSION 1 FILED
- 28 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 27 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Apr 2025 — PUBLISHED FOR OPPOSITION
- 26 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 17 Sept 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 17 Sept 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 06 Sept 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED